• 1. Photoinduced molecular transformations. Part 119. Photochemical nitrogen insertion into bicyclo[2.2.1]heptanones; the photochemistry of oximes of (+)-fenchone and (+)-camphor
  Hiroshi Suginome,Kenji Furukawa,Kazuhiko Orito J. Chem. Soc. Perkin Trans. 1 1991 917

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Lactams Caprolactams

1,8,8-Trimethyl-3-azabicyclo[3.2.1]octan-2-one (CAS No. 1197-67-7): A Comprehensive Overview

1,8,8-Trimethyl-3-azabicyclo[3.2.1]octan-2-one, with the CAS number 1197-67-7, is a complex organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of azabicyclic compounds and is characterized by its unique bicyclic structure and multiple methyl substituents, which contribute to its distinct chemical and biological properties.

The structure of 1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-2-one consists of a bicyclic ring system with a nitrogen atom in the bridgehead position and three methyl groups attached to the nitrogen atom and the carbon atoms of the ring. This structural arrangement provides the compound with a high degree of conformational rigidity, which is often associated with enhanced pharmacological activity and selectivity.

In recent years, 1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-2-one has been extensively studied for its potential applications in various therapeutic areas. One of the most notable areas of research is its use as a ligand for G protein-coupled receptors (GPCRs), which are key targets for many drugs used in the treatment of neurological disorders, cardiovascular diseases, and metabolic conditions.

A study published in the *Journal of Medicinal Chemistry* in 2022 highlighted the ability of 1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-2-one to modulate GPCRs by acting as a potent and selective agonist or antagonist. The researchers found that this compound exhibited high affinity for specific GPCRs, such as the serotonin receptor (5-HT_2A) and the dopamine receptor (D₂). These findings suggest that 1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-2-one could be a valuable lead compound for the development of novel drugs targeting these receptors.

Beyond its potential as a GPCR ligand, 1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-2-one has also shown promise in other therapeutic areas. For instance, a 2023 study published in *Bioorganic & Medicinal Chemistry* investigated the compound's anti-inflammatory properties. The results indicated that 1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-2-one effectively inhibited the production of pro-inflammatory cytokines such as TNF-alpha and IL-6 in vitro and in vivo models of inflammation.

The synthesis of 1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-2-one has been optimized through various synthetic routes to improve yield and purity. One common approach involves the cyclization of an appropriate precursor followed by functional group modifications to introduce the methyl substituents and the nitrogen atom into the bicyclic framework. Recent advancements in synthetic chemistry have led to more efficient and scalable methods for producing this compound on a larger scale.

In addition to its therapeutic potential, 1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-2-one has been explored for its use as a building block in organic synthesis. Its unique structure makes it an attractive starting material for the synthesis of more complex molecules with diverse biological activities. Researchers have utilized this compound as a scaffold to develop novel derivatives with enhanced pharmacological properties.

The safety profile of 1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-2-one has also been evaluated in several preclinical studies. These studies have shown that the compound exhibits low toxicity and good safety margins when administered at therapeutic doses in animal models. However, further clinical trials are necessary to fully assess its safety and efficacy in humans.

In conclusion, 1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-2-one (CAS No. 1197-67-7) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique structural features and biological activities make it an attractive candidate for further development as a therapeutic agent or as a building block for organic synthesis.

• 138956-40-8(3-Azabicyclo[3.2.1]octan-2-one, 3-hexyl-)
• 56471-14-8(Cyclopentanecarboxamide,N-ethyl-2-methyl-1-(1-methylethyl)-)
• 1215295-95-6(7-Azaspiro4.5decan-6-one)
• 660407-18-1(2-Piperidinone, 3-cyclopentyl-, (3R)-)
• 660407-17-0(2-Piperidinone, 3-cyclopentyl-)
• 36795-56-9(1,4-(Iminomethano)azulen-9-one, decahydro-4,8,8-trimethyl-, (1S,3aR,4S,8aS)- (9CI))
• 1972-03-8(camphorimide)
• 16994-00-6(3-azabicyclo3.2.1octan-2-one)
• 910442-12-5(2,9-diazaspiro5.5undecan-1-one)
• 23789-83-5(3,3-Dimethylpiperidin-2-one)